🏆 Deal of the Week · CW 14/2024
Neurosterix raised USD 63 million in a Series A round in April 2024; the post-money valuation was not disclosed. The round was led by Perceptive Life Sciences and Perceptive Advisors, with participation from Acorn Bioventures.
Neurosterix — key deal facts
| Company | Neurosterix |
| Founded | 2024 |
| Headquarters | Geneva, Switzerland |
| Amount raised | USD 63M |
| Valuation | Valuation Remains Undisclosed |
| Round | Series A |
| Investors | Perceptive Life Sciences Perceptive Advisors Acorn Bioventures |
| Sectors | Biotechnology |
Who invested in Neurosterix?
The syndicate comprises Perceptive Life Sciences, Perceptive Advisors, and Acorn Bioventures. The participation of two distinct Perceptive vehicles signals a high-conviction institutional bet on the allosteric modulator space. Acorn Bioventures adds a specialist bioventures perspective to the cap table at the company's earliest stage.
What does Neurosterix do?
Neurosterix is a biopharmaceutical company headquartered in Geneva, Switzerland, founded in 2024. It develops allosteric modulators designed to fine-tune brain signaling for the treatment of neuropsychiatric and neurological disorders. Lead pipeline assets include an M4 positive allosteric modulator (PAM) targeting schizophrenia, an mGlu7 negative allosteric modulator (NAM) for mood disorders, and an mGlu2 NAM aimed at cognitive impairment, each advancing through IND-enabling studies or clinical candidate selection. The company is led by CEO Tim Dyer, who concurrently serves as CEO of Addex Therapeutics.
Neurosterix valuation & multiples
Explore the benchmarks: Series A.
Frequently asked questions
How much did Neurosterix raise in its Series A?
Neurosterix raised USD 63 million in its Series A round, which closed in April 2024.
What is Neurosterix's valuation?
Neurosterix's post-money valuation was not disclosed at the time of the Series A announcement.
Who invested in Neurosterix?
The Series A was led by Perceptive Life Sciences and Perceptive Advisors, with participation from Acorn Bioventures.
When was Neurosterix founded and where is it based?
Neurosterix was founded in 2024 and is headquartered in Geneva, Switzerland.
Source: original announcement — read the full report.